Rubenstein, E B <br/><br/>
Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.  [electronic resource] 

 -  Cancer  Mar 1997 
 - 1216-24 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Antiemetics--administration & dosage<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Cyclophosphamide--adverse effects<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Doxorubicin--adverse effects<br/>Female<br/>Humans<br/>Indoles--administration & dosage<br/>Male<br/>Middle Aged<br/>Nausea--chemically induced<br/>Quinolizines--administration & dosage